Alnylam Pharmaceuticals
ALNY
#872
Rank
$20.95 B
Marketcap
$165.70
Share price
5.27%
Change (1 day)
-16.76%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of March 2024 : $4.04 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are $4.04 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31$4.05 B9.34%
2022-12-31$3.70 B21.26%
2021-12-31$3.05 B27.78%
2020-12-31$2.39 B149.97%
2019-12-31$0.95 B250.55%
2018-12-31$0.27 B19.51%
2017-12-31$0.22 B-33.36%
2016-12-31$0.34 B181.28%
2015-12-31$0.12 B-15.02%
2014-12-31$0.14 B-4.56%
2013-12-31$0.15 B-2.14%
2012-12-31$0.15 B-6.38%
2011-12-31$0.16 B-30.26%
2010-12-31$0.23 B-22.54%
2009-12-31$0.30 B-13.94%
2008-12-31$0.35 B19.66%
2007-12-31$0.29 B658.71%
2006-12-31$38.83 M6.19%
2005-12-31$36.56 M83.17%
2004-12-31$19.96 M-67.74%
2003-12-31$61.89 M198.16%
2002-12-31$20.75 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
$54.57 B 1,249.72%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$57.61 B 1,324.77%๐Ÿ‡ซ๐Ÿ‡ท France
$7.37 B 82.47%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.26 B-44.03%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.55 M-99.84%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.72 B-82.16%๐Ÿ‡บ๐Ÿ‡ธ USA
$35.23 B 771.24%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
$0.45 B-88.63%๐Ÿ‡บ๐Ÿ‡ธ USA